. Number above boxplot refers to percent detection. Numbers of samples for each site are indicated next to the site name. 25 samples were analyzed for carisoprodol at the site downstream of site NY1 effluent, and 26 samples were analyzed for carisoprodol downstream of NY2 and NY3 effluent sites. An asterisk (*) denotes that concentrations for methadone were not quantified due to poor and inconsistent recovery in spikes of streamwater; the percent of samples with a detection for methadone are given above the asterisk. Dashed line at bottom of boxplot or whisker denotes method detection limit.
S-5
Supplemental Figure S-4. Ratio of butalbital and carisoprodol concentrations in downstream water to concentration in NY2 effluent versus the percentage of WWTP effluent contribution to streamflow. r refers to Spearman rank correlation, and p is the corresponding probability value. S-6 Supplemental 
INTRODUCTION
The results contained in this supplemental material section provides 1) a description of the analytical method used for the results discussed in this paper and 2) performance characteristics of the method, including a holding time study. The seven pharmaceuticals reported in this study were initially reported as tentatively identified compounds (TICS) in wastewater treatment plant (WWTP) effluent samples analyzed for 61 anthropogenic waste indicator compounds (6) Authentic standards for the pharmaceuticals included in the study were subsequently obtained and a method implemented to provide quantitative data for the target pharmaceuticals in samples collected from these sites from July 2004 through October 2009. Unexpectedly, observed concentrations ranged over several orders of magnitude and were substantially higher than any reported for these or other pharmaceuticals in waters of the United States, therefore some method performance data was necessarily calculated after sample analysis began. The supplemental information provided herein is provided to enable the reader to evaluate the data generated by the method, and to put the data presented in this study in the context of method performance.
METHOD DESCRIPTION
Determination of the seven pharmaceuticals measured in this study (Table S-6) was based upon a previously described method that was used for the determination of 61 compounds typically found in domestic and industrial wastewater (6) .
Sample Preparation, Apparatus and Instrumentation, and Standards
One-liter samples were filtered through 0.7-μm glass-fiber filters. After filtration, three surrogate compounds (Table S-6) were added to each environmental and/or qualitycontrol sample to monitor sample-specific method performance. Samples were extracted by vacuum through 500 mg OASIS-HLB-SPE cartridges (Waters Inc., catalog number 186000115) using a custom extraction manifold (6) . SPE Cartridges were eluted with dichloromethane:diethyl ether, 80:20 volume per volume. Internal standards were added to sample extracts before the sample extracts are evaporated to 0.4-mL, placed in a 1.5 mL autosampler vial and held at -4 degrees C until instrumental analysis. Laboratory reagent blank and spike samples were prepared with each set of up to 10 environmental samples. S-11 Sample extracts were analyzed by capillary gas chromatography/mass spectrometry (GC/MS, Agilent Technologies model 6890 GC and model 5973 MS) and operated under full scan conditions using electron impact ionization at 70 electron volts.
The GC conditions were:
Column: HP Ultra II (5 % phenylmethyl silicone), 30 m x 0.25 mm, 0.50 μm film thickness.
Carrier gas: ultra high purity helium with a linear-flow velocity of 32 cm/sec. Authentic standards were obtained for the seven pharmaceuticals that were included in the study. Metaxalone and phendimetrazine standards were obtained from Toronto Research Chemicals. All the remaining standards were obtained from Fisher Scientific. Purity for all compounds were 99% or better.
Analytes were required to meet qualitative identification criteria prior to quantification. The qualitative criteria include comparison with the authentic reference standard for confirmation of GC retention time and mass spectral performance. This requires that the suspected analyte GC retention time was within +/-0.05 minute of that of the authentic standard and the mass spectral quantitation ion and two confirmation ion abundance ratios were within +/-20% of the values determined by analysis of the authentic standard under identical experimental conditions. Analytes that meet these qualitative criteria were then quantified using the injection internal standard method using a 5-8 point calibration curve (6). 
Calibration Curves
The method used in this study was initially set up to detect expected low environmental concentrations of the target compounds. The initial maximum calibration point for most compounds was 40 μg/L, except diazepam (4 μg/L) and metaxalone (400 μg/L). Because concentrations of many compounds in WWTP effluent samples from NY2 and NY3 consistently exceeded the highest point on the calibration curve, the method was slightly modified in 2009 to provide the ability to quantify larger concentrations. Maximum calibration points were extended to allow for quantitation over a broader range of concentrations, and calibration curves were extended to 400 μg/L for all compounds except metaxalone (4000 μg/L). , concentrations were quantified above the maximum calibration point by either 1) diluting samples, 2) extracting lesser amounts of sample, or 3) analysis of frozen archived samples using the higher calibration curves. Overall, much of the data from site NY3 effluent samples were affected by the calibration curve dynamic range limitation, with between 20-60% of samples right-censored for butalbital, metaxalone, methadone, and oxycodone. A few samples (less than 20%) for carisoprodol and butalbital were right-censored at 40 μg/L in NY2 effluent samples. Some low-level concentrations were estimated between the MDL and the lowest point on the calibration curve, particularly for samples collected before August 2007, but these estimated values were generally within 50% of the lowest point on the calibration curve.
METHOD PERFORMANCE
The measures of method performance discussed below reflect (1) method performance results collected over the entire period when environmental samples were analyzed and (2) specific method performance evaluations made after the range of concentrations likely to occur was better understood.
Reagent Set Spike Samples
Reagent set spike samples were reagent water samples fortified with known amounts of the seven pharmaceuticals and processed with a set of environmental samples. The final fortification concentration reflects the sensitivity of each compound in the analysis. Individual reagent spike samples were used to evaluate set-specific method performance in the absence of sample matrix components. The individual reagent set spike results can be used to assess overall method bias and precision by aggregating individual reagent set spike samples and calculating mean recoveries and relative standard deviations (RSDs).
Reagent set spike data were divided into two periods corresponding to different spiking concentrations. Reagent set spike data for analysis before 2009 are given in Table S-7 , and those after 2009 are given in Table S-8. Spiking concentrations were higher for the reagent set spikes analyzed before 2009; spiking concentrations were decreased for analyses in 2009 to better coincide with concentrations typically present in samples. Analysis of reagent set spike recoveries over the duration of the study indicated no temporal trends, suggesting method performance stability over the course of the study. The difference in pre-2009 and 2009 reagent set spike recoveries and RSDs was likely due to the difference in spiking levels and to a lesser extent the difference in the number of spikes between the two periods. Mean reagent set spike recoveries for both sets of reagent set spike data ranged from 66-140%, and RSDs were generally less than 30%. The only mean reagent set spike outside the 60-130% range was the low-concentration carisoprodol spike (140%). Only two RSDs were greater than 30%: RSDs for the oxycodone low-concentration and highconcentration spikes were 34 and 46%, respectively.
Matrix Spike Recoveries
Reagent set spike recoveries reflect method performance in the absence of coextracted sample matrix components. In order to better assess these contrasting matrix effects on the seven pharmaceuticals in this study, replicate samples from three different wastewater sources and a stream sample below one of these wastewater discharges were fortified with all or a select group of these pharmaceuticals and recoveries determined after correction for ambient compound concentrations from analysis of two or more unspiked replicates.
S-15
The four samples spiked were: 1) an NY3 effluent spiked at high concentrations (5-4000 μg/L), 2) an NY1 effluent spiked at moderate (0.8 to 80 μg/L) concentrations, 3) an NY4 effluent spiked at low (0.2 μg/L) concentrations, and 4) a stream sample collected upstream of the NY1 WWTP discharge (hereafter referred to as the NY1 upstream sample) spiked at low-moderate concentrations (0.08 to 8 μg/L). The number of replicate spikes ranged from five to 13 for each matrix spike. These matrices included various wastewaters with a wide range of expected pharmaceutical concentrations and a streamwater with no effluent discharge. For the five pharmaceuticals with available data, mean recoveries and RSDs of pharmaceuticals fortified with high concentrations in samples of NY3 effluent (Table S-9) were similar to recoveries and RSDs observed in reagent spikes (Tables S-7 , S-8). All analytes had recoveries between 60-130%, and RSDs were all less than 30%. Mean recoveries and RSDs of pharmaceuticals fortified with moderate concentrations in samples of NY1 effluent (Table S-10) were similar to recoveries and RSDs observed in reagent set spikes (Tables S-7 , S-8) and those in the NY3 effluent samples (Table S-9). All but one of the mean recoveries were within the 60-130% range, and all RSDs were <30%. The only recovery outside the 60-130% range was methadone, at 59%. As was the case for NY3 effluent spikes, many of these pharmaceuticals had RSDs that were lower in these matrix spikes than in reagent set spikes. This is attributed to the analysis of these samples in a single set, whereas the reagent set spikes were analyzed in multiple sets over several years.
NY3 Effluent Matrix

NY1 Effluent Matrix Spiking
NY4 Effluent Matrix Spiking Results:
A single composite sample of NY4 effluent collected in May 2009 was divided into 13 replicate one-Liter samples and fortified with the analytes at low (0.2 μg/L) concentrations to assess method performance for low pharmaceutical concentrations in wastewater-enriched environmental samples. Any ambient environmental contributions of pharmaceuticals to the matrix spike replicates were corrected for by triplicate analysis of unspiked samples. These 13 replicate samples were extracted in 5 different extraction sets and then analyzed in a single analytical set.
Results for the spiked analytes are listed in Table S -11. These samples were also used for a holding time study (see below). Data for all the analytes but phendimetrazine are available; the data for phendimetrazine from the NY4 effluent spike holding time experiment are not included because there was a significant decrease in the concentration for this analyte over the 15 day holding time experiment. Thus, with the exception of phendimetrazine, the aggregated results could also be used as a matrix spike recovery experiment. Five of the six analytes with available data had mean percent recoveries within the 60-130% range, and all but one of the RSDs were <30%. Recoveries for oxycodone (170%) were higher than most other analytes for these spikes, but the RSD was low (8.8%). Only the methadone RSD exceeded 30% (31%). For most analytes, the recoveries were higher and RSDs were similar to those for reagent set spikes (Table S-7 and S-8) and other matrix spikes (Tables S-9-S-11). The high mean recovery for oxycodone in this spike may reflect the low spiking level used in this experiment.
NY1 Upstream Matrix Spikes:
A single composite sample of streamwater upstream of NY1 collected in March 2007 was divided into 5 replicate one-Liter samples and fortified with target anlaytes at low (0.08 to 8 μg/L) concentrations to assess method performance for low pharmaceutical concentrations in environmental waters with negligible wastewater content. These samples were extracted and analyzed in a single analytical set. Any ambient environmental contributions of pharmaceuticals to the matrix spike replicates were corrected for by duplicate analysis of unspiked samples. Results for the seven spiked pharmaceuticals are listed in Table S -12. Four analytes (butalbital, carisoprodol, diazepam, and metaxalone) had mean recoveries between 60-130%, and five had RSDs<30%. Two pharmaceuticals (oxycodone and phendimetrazine) had recoveries of 57% and RSDs between 23 to 36%. Methadone had a low recovery (32%) and high RSD (48%) for this spike. Mean recoveries and RSDs of pharmaceuticals fortified with low concentrations in streamwater samples from upstream of the NY1 WWTP (Table S-12) were somewhat lower than the recoveries and RSDs observed in reagent set spikes (Tables S-7 , S-8) and in the matrix spikes from effluent samples (Tables S9-S11 ) for some analytes.
Summary of Reagent Set and Matrix Spikes
Data from the different spiking experiments (two reagent set spike experiments at low and medium concentrations, three effluent spike experiments at low, medium and high concentrations, and a stream spike experiment at medium concentrations) show that median mean recoveries for all spikes were 94%, and median RSDs were 15%. Of the 14 reagent set spikes, only the mean recovery for the low concentration (0.2 μg/L) carisoprodol spike (140%) lies outside the 60-130% range, and only the two oxycodone spikes (low level at 46% and high level at 34%) have RSDs>30%. Of the 19 effluent spikes, two mean recoveries --methadone for the moderate spike (59%) and oxycodone for the low-level spike (170%) have mean recoveries outside the 60-130% range. Only one of the 19 effluent spikes, the low level methadone spike, has an RSD >30% (31%).
The spiking results show that the effluent concentrations for the seven pharmaceuticals in this study have low bias and variability. Although the low-level reagent spikes indicate S-19 that carisoprodol may have a positive bias for low concentrations, the other reagent spike and effluent spikes for carisoprodol ranged from 99-104%, suggesting no bias. The methadone spike recovery for the effluent spike at middle range (8 μg/L) concentrations indicates a slight low bias, yet the other two methadone effluent spikes for low (0.2 μg/L) and high (>=90 μg/L) range concentration (63 and 91%, respectively) show no bias. The results indicate a positive bias for oxycodone for low (0.2 μg/L) effluent concentrations, yet the two other oxycodone effluent spikes for moderate (8 μg/L) and high (>=24 μg/L) concentrations have recoveries of 94 and 70%, respectively. The high RSDs for reagent set spikes suggest that oxycodone concentrations may be more variable than other pharmaceuticals in this study, however the effluent spikes for oxycodone all have RSDs<30%.
The stream spike recoveries for butalbital, carisoprodol, diazepam and metaxalone were between 60-130%, and RSDs were less than 30%, indicating low bias and variability. Because of the low (32%) and variable (RSD of 48%) recovery for methadone stream spikes, stream water data for methadone are only reported qualitatively (as percent detection). The low recoveries for stream spikes for oxycodone and phendimetrazine (57%) suggest that the stream concentrations for these two pharmaceuticals may be biased low. In addition, the RSD for the oxycodone stream spike was 36%, indicating a higher variability for stream concentrations for this pharmaceutical than the others.
Method Detection Limit
The determination of method detection limits (MDLs) for each pharmaceutical was conducted according to the procedures of the U.S. Environmental Protection Agency (7), and are presented in Table S -13.
The MDLs were determined using a low-level reagent spike study that employed multiple experiments in order to ensure that the lowest appropriate spiking level was used to calculate each individual MDL. These experiments resulted in data that provides reagent set spike recoveries near the detection limit as well as MDLs, and are discussed together in this section. Two fortification concentrations were used. Ten reagent water samples were fortified at 0.05 μg/L for each compound, extracted, and analyzed. These samples were analyzed in the same analytical set. Seven reagent water samples were fortified at 0.2 μg/L for each compound, extracted, and analyzed. These samples also served as set spikes, and were prepared and analyzed in different analytical sets. Details on the mean recoveries, %RSDs, and calculated MDLs at both fortification concentrations are shown in Table S-13. Five of the seven pharmaceuticals (butalbital, carisoprodol, diazepam, metaxalone, and phendimetrazine) were reliably detected in the 0.05 μg/L fortification samples, and the MDLs at this fortication were used as MDLs in the study (Table S-13 ). The remaining two pharmaceuticals (methadone, oxycodone, and methocarbamol) were detectable at 0.20 μg/L (Table S-13) . Although a mean recovery could be calculated for methadone in the 0.05 μg/L fortification level, methadone was only detected in 7 of the 10 samples fortified at 0.05μg/L, so the results of the 0.20 μg/L fortification level were used for methadone. Mean recoveries and RSDs of the 5 pharmaceuticals reliably detected at the 0.05 μg/L fortification were comparable with the mean recoveries and RSDs at the 0.2 μg/L fortification and in the range typical for reagent set spikes (see Table S -7, S-8) .
Mean recoveries and RSDs at the 0.2 μg/L fortification were all comparable with mean recoveries and RSDs in the reagent set spike results (Table S- The results for the low-level reagent spike/MDL study indicate that the concentrations chosen were appropriate for estimating the MDL. Based on the guidance provided in (7), the MDLs calculated for five analytes at the 0.05 μg/L fortification level were appropriate, given the sensitivity of the method for these five compounds. The spiking level for the MDLs used in this study are appropriate for these compounds, falling within the 1-5 times the calculated MDL. . S-21 In order to better understand precision in the analysis of environmental samples, 18 replicates of a homogeneous sample of NY3 effluent were analyzed and method precision calculated. These were prepared for analysis in five different preparation sets but instrumental analysis was conducted as a single set. These samples were also used for a holding-time study (see below), and thus the calculated precision better incorporates sources of variation associated with different preparation sets. The results for this experiment are shown in Table S-14. Because these data represent the environmental concentrations in NY3 effluent at the time of sample collection, all compounds were not present. Most compounds (5 of 7) were detected in the sample of NY3 effluent, allowing for the assessment of precision for most of the pharmaceuticals included in the study; the RSDs for these 8 compounds ranged from 6.4% to 27%. This precision was comparable with other estimates of environmental precision made for pharmaceuticals and wastewater indicator compounds included in previous studies (8) .
Estimation of Precision at Ambient Environmental Concentrations
Summary of Method Performance
The results of the spiking experiments suggest the method performed acceptably for the seven target pharmaceuticals in effluent samples, and for six pharmaceuticals in surface water samples. Because of the low methadone stream spike recoveries, discussion of surface water concentrations is limited to six pharmaceuticals (butalbital, carisoprodol, diazepam, metaxalone, oxycodone, and phendimetrazine), with methadone only reported as qualitatively detected in stream samples. These results also indicate that concentrations S-22 of oxycodone at low concentrations in streams and effluent may be somewhat more variable than other concentrations presented in this study.
Holding Time Studies
The method of analysis used in this study was based upon a recommended holding time (6) of up to 14 days for filtered water samples. However, since these samples were comprised of treated wastewater, separate holding time studies were conducted in order to assess whether the maximum recommended 14 day holding time would introduce systematic low bias into the results as a result of potential degradation of the seven target pharmaceuticals. Two studies were conducted using multiple splits of samples collected at the NY3 and NY4 WWTP sites, as previously discussed above. The NY4 sample splits were fortified with the seven pharmaceuticals and replicates analyzed over a 14 day period. The NY3 replicate samples were not fortified and were also analyzed over a 14 day period. Two experiments were conducted to include an assessment of long holding times for a range of wastewater treatment matrices, as the NY3 effluent was from an activated sludge wastewater plant, and the NY4 effluent was from a rotating biologic contactor wastewater plant. These data are useful for ensuring that holding time information was available for all seven pharmaceuticals included in the study, and to indicate whether results would be different for unfortified samples at high concentrations (NY3) and fortified samples at low concentrations (NY4).
NY3 Hold Time Study
Eighteen NY3 replicate effluent samples were analyzed to determine compound degradation in sample matrix with respect to time. None of these samples were fortified, because they contained high ambient environmental concentrations of five of the seven target pharmaceuticals. Three samples were extracted within 24 hours of sampling. Three samples were extracted three days from collection then three more on days five, seven, eleven, and fifteen. Linear regression analysis of concentration versus hold time was performed to calculate a degradation rate. This rate was used to determine the percent of analyte lost to degradation in fifteen days. The results of the holding time study for these unfortified samples are shown in Table S-16 .
NY4 Holding time Study
Sixteen NY4 replicate effluent samples were studied to determine compound degradation in sample matrix with respect to time; all of the 16 replicate samples were collected within a short (less than 2 hour period) on the same day. Because the NY4 WWTP uses rotating biologic contactors for biologic treatment, it is expected that this matrix represents WWTPs that are less efficient at removing a variety of wastewater compounds than sites using activated sludge for biologic wastewater removal. Thirteen of the 16 replicate samples were fortified in the field at 0.2 μg/L for all seven target pharmaceuticals at the time of collection; three of the 16 replicate samples were not fortified. The three unspiked samples and three spiked samples were extracted within 24 hours of sampling. Three samples were extracted three days from collection and three more seven days from collection. Two samples were extracted 11 days from collection and two more were extracted 15 days from collection. Linear regression analysis of concentration versus hold time was performed to determine a degradation rate for each pharmaceutical. This rate was used to determine the percent of analyte lost to degradation in 15 days. The rates for all seven target pharmaceuticals are shown in Table  S -15. 
Summary of Holding Time Results
In both sample matrixes, four pharmaceuticals (carisoprodol, methadone, oxycodone, and metaxalone) had small (<8%) changes in concentrations over the 15 days for both NY3 and NY4 samples (Table S-15) . Two other pharmaceuticals only detected in the NY4 effluent (carisoprodol and diazepam) also had small (<8%) changes in concentrations after 15 days (Table S-15) . The remaining pharmaceutical, phendimetrazine had slight changes (1.2%) in concentrations in NY3 effluent samples, but large (45%) decreases in concentrations in NY4 effluent spikes at 15 days. The lower concentrations in NY4 effluent spikes for phendimetrazine indicate that this sample matrix may result in degradation of this analytes in samples over 15 days. Overall, for most of the target pharmaceuticals, there was little indication of positive or negative bias over 15 days, but some effluent matrices may result in the decrease in concentrations for phendimetrazine and over a 15 day holding time. The median holding times for the environmental samples included in the study was 8 days, and the holding time for 90% of the samples did not exceed 15 days. Thus, the combination of small changes in concentrations for most analytes and the low holding times for most samples indicate that holding time between sample collection and extraction did not greatly affect pharmaceutical concentrations reported in this study.
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Additional Compounds Qualitatively Identified in Samples
All of the pharmaceuticals reported as 'Pharmaceuticals Qualitatively Identified in Samples Using a Standard, but not Quantified ' in Tables S-4 and S-5 were identified qualitatively using standards in at least two samples collected between 2008-2009. Authentic standards were obtained for the additional 18 pharmaceuticals listed in Table  S-4 and S-5, and these analytes met qualitative identification criteria. Four of these compounds (chlorpheniramine, codeine, hydrocodone and methocarbamol) were originally included in method development spike experiments for this study, but due to low and or inconsistent recoveries concentrations for these compounds are not reported, but their presence was noted in multiple samples from these sites.
The qualitative criteria include comparison with the authentic reference standard for confirmation of GC retention time and mass spectral performance. This requires that the suspected analyte GC retention time was within +/-0.05 minute of that of the authentic standard and the mass spectral quantitation ion and two confirmation ion abundance ratios were within +/-20% of the values determined by analysis of the authentic standard under identical experimental conditions. Ions used for qualification are listed in Table S-16. S-25 
